Rapport Therapeutics, Inc.
- Last sale
- Nov 2, 2026 · +0.36%
- Market cap
- $1.49B
- 59.28M shares
- Filings
- 254
Q3 2026
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−7.3% FY25 yoy
- $1.49B
- —
- —
- 3.8×
- -5.92%
- —
FY2025 figures · derived
Price
Nov 2, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
No annual history for this metric yet.
| Period | Ended | Value | Kind | Source trail |
|---|
Pharmaceutical preparations
Rapport Therapeutics, Inc. is the 115th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
RAREUltragenyx Pharmaceutical Inc.$673.0M20.2%85.4%$1.6BTYRATyra Biosciences, Inc.———$1.5B
RAPPRapport Therapeutics, Inc. (this company)———$1.5B
ETONEton Pharmaceuticals, Inc.$80.0M104.9%5.8%$1.5BPCRXPacira BioSciences, Inc.$726.4M3.6%1.0%$1.5BPAHCPhibro Animal Health Corp$1.5B17.1%6.6%$1.4BNUVBNuvation Bio Inc.$62.9M699.0%325.3%$1.4BKRSAKorsana Biosciences, Inc.$2.1M3.7%170.1%$1.4BANABAnaptysbio, Inc$234.6M157.0%5.6%$1.4BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Rapport Therapeutics, Inc. · CIK 2012593 · Engraved from SEC EDGAR